^
    Back
    Association details:
    Biomarker:Low NLR
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Front Immunol
    Title:

    Clinical markers predict the efficacy of several immune checkpoint inhibitors in patients with non-small cell lung cancer in China

    Published date:
    12/21/2023
    Excerpt:
    Low baseline NLR in peripheral blood and high expression of CD8 in tissues are associated with longer PFS and may have a potential predictive value for patients with stage III-IV NSCLC using ICIs.
    DOI:
    10.3389/fimmu.2023.1276107